tranilast and Myocarditis

tranilast has been researched along with Myocarditis* in 3 studies

Other Studies

3 other study(ies) available for tranilast and Myocarditis

ArticleYear
SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?
    European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:17

    NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.

    Topics: Betacoronavirus; Cardiovascular Diseases; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Cytokines; Humans; Inflammasomes; Myocarditis; Nitriles; NLR Family, Pyrin Domain-Containing 3 Protein; ortho-Aminobenzoates; Pandemics; Pneumonia, Viral; Prognosis; SARS-CoV-2; Venous Thromboembolism

2020
[Tranilast inhibits myocardial fibrosis in mice with viral myocarditis].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2016, Volume: 18, Issue:5

    To investigate the effect of tranilast on myocardial fibrosis in mice with viral myocarditis (VMC).. Male balb/c mice (n=72) were randomly divided into control, VMC and tranilast groups (n=24 each). In the VMC and tranilast groups, the mice were infected with Coxsackie virus B3 (CVB3) to prepare VMC model, while the control group was treated with Eagle's medium. After modeling, the tranilast group was administrated with tranilast [200 mg/(kg.d)] until the day before sampling. On days 7, 14 and 28 after CVB3 or Eagle's medium infection, heart specimens (n=8) were taken and examined after Toluidine blue staining and Nissl staining for counts of mast cells (MC), hematoxylin-eosin staining for myocardial pathological changes, and Masson staining for myocardial fibrosis. The expression of CTGF and type I collagen (Col I) in the myocardial tissue was measured by RT-PCR and Western blot. The correlations of CTGF mRNA expression with MC counts and Col I expression were analyzed.. The myocardial pathological changes and collagen volume fraction in the VMC group were significantly higher than in the control group at all three time points (P<0.05). Tranilast treatment significantly decreased the myocardial pathological changes and collagen volume fraction compared with the VMC group (P<0.05). The mRNA and protein expression of CTGF and Col I increased in the VMC group compared with the control group, and the increases were reduced with tranilast treatment (P<0.05). The number of MC was positively correlated to CTGF mRNA expression on the 7th day and 14th day (r=0.439, P=0.049) in the VMC group. There were positive correlations between the mRNA expression of Col I and CTGF on the 7th day and 14th day (r=0.646, P=0.007) and the 28th day (r=0.326, P=0.031).. Tranilast may inhibit the aggregation of MC and down-regulate the expression of CTGF, relieving myocardial fibrosis of mice with VMC.

    Topics: Animals; Collagen Type I; Connective Tissue Growth Factor; Coxsackievirus Infections; Enterovirus B, Human; Fibrosis; Male; Mice; Mice, Inbred BALB C; Myocarditis; Myocardium; ortho-Aminobenzoates; RNA, Messenger

2016
[Effect of tranilast on myocardial fibrosis in mice with viral myocarditis].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2014, Volume: 16, Issue:11

    To study the role of tranilast in the pathogenesis of myocardiac fibrosis in viral myocarditis.. Seventy-two BALB/C mice were randomly divided into control, model and intervention groups (n=24 each). Mice in the model and intervention groups were infected with Coxsackievirus B3 to induce viral myocarditis. The intervention group was given with tranilast (200 mg/kg) by gavage until sacrifice for sampling, while the other two groups were administered with the same volume of normal saline. Cardiac tissues were obtained from 8 mice on 7, 14 and 28 days after modeling. The mast cell number was observed by toluidine blue staining and thionine staining. The cardiac tissues were stained with hematoxylin and eosin as well as masson trichrome to observe the pathological changes in cardiac tissues. The mRNA and protein expression of osteopontin and transforming growth factor-β1 was measured by RT-PCR and immunohistochemistry respectively.. In the model group, the mRNA and protein expression of osteopontin reached the highest level on the 7th day, decreasing from the 14th day, and became to the least on the 28th day; while the expression of TGF-β1 increased from the 7th day, reaching a peak on the 14th day, and decreased slightly on the 28th day. The mRNA and protein expression of TGF-β1 and OPN was lower in the intervention group than the model group (P<0.05), but higher than the control group (P<0.05). The expression of OPN mRNA was positively correlated to the number of mast cells.. Tranilast can reduce myocardial fibrosis by decreasing the number of mast cells, inhibiting the expression of TGF-β1 and OPN.

    Topics: Animals; Fibrosis; Male; Mast Cells; Mice; Mice, Inbred BALB C; Myocarditis; Myocardium; ortho-Aminobenzoates; Osteopontin; Transforming Growth Factor beta1

2014